Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of Approval
Olanzapine ER is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Schizophrenia. According to GlobalData,...
Emrusolmin by Teva Pharmaceutical Industries for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration): Likelihood of Approval
Emrusolmin is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Multiple System Atrophy (MSA or...
Fremanezumab by Teva Pharmaceutical Industries for Rosacea: Likelihood of Approval
Fremanezumab is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Rosacea. According to GlobalData, Phase...
TV-46046 by Teva Pharmaceutical Industries for Female Contraception: Likelihood of Approval
TV-46046 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Female Contraception. According to GlobalData,...
Omalizumab biosimilar by Teva Pharmaceutical Industries for Chronic Urticaria Or Hives: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Chronic Urticaria Or Hives....
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Omalizumab Biosimilar?
Omalizumab Biosimilar is a monoclonal antibody commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Chronic Urticaria...
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Denosumab Biosimilar?
Denosumab Biosimilar is a monoclonal antibody commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Post Menopausal...
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Wet (Neovascular...